AstraZeneca has won its fight to prevent Handa Pharmaceuticals from selling a generic version of its anti-psychotic drug Seroquel XR in the US until late 2016.
Shares in the British drug manufacturer were up 0.6% by 0855 GMT on Friday, on news it had reached a patent settlement.
Go deeper with GlobalData
The news does not resolve patent battles with other generic drug manufacturer, but because Handa was the first generics company to file for approval of its version of the drug, the settlement could block other copies out of the US until Handa launches, reports Reuters.
AstraZeneca has also said that technologies to extend the time the medicine remains in the bloodstream will also protect Seroquel XR from 2012 to November 2017.
Seroquel XR is an extended-release oral drug approved for the treatment of schizophrenia.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
